Category: Market/Novel Tech

Month: 16 Aug 2012

Issue: not yet available

ThromboGenic’s ocriplasmin revenues may benefit from Belgian patent income treatment

ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on the development of ocular treatments has announced that the Belgian tax authorities have granted the company a positive ruling under the “patent income deduction regime”. The Belgium-based incentivisation scheme should allow ThromboGenics to benefit from a reduced tax rate for all patent related income arising from the company’s lead ocriplasmin product. On July 27th, the company announced it had received a US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee recommendation that ocriplasmin be approved for the treatment of symptomatic vitreomacular adhesion (VMA).

Back to previous

Related News

Gearoid Tuohy

editor

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the December 4th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]